Small Cap Stocks To Follow Now – July 13th

SK hynix, Twin Vee PowerCats, Agenus, Q32 Bio, and Direxion Daily PLTR Bear 1X Shares are the five Small Cap stocks to watch today, according to MarketBeat’s stock screener tool. Small cap stocks are shares of publicly traded companies with relatively small market capitalizations, typically ranging from a few hundred million to a few billion dollars. For stock market investors, they often offer higher growth potential than larger companies, but they can also be more volatile and carry greater risk. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

SK hynix (SKHY)

We are one of the world’s largest memory semiconductor companies and engage in the design, manufacture and sale of advanced memory semiconductors. In the DRAM market that includes HBM, we were ranked second globally based on revenue with a market share of 29.1% in the first quarter of 2026, according to market research conducted by IDC.

Twin Vee PowerCats (VEEE)

Twin Vee PowerCats Co. engages in the design, manufacture, and sale of recreational and commercial power catamaran boats. The firm is focused on designing and developing its products under the ELECTRA Power Sports brand. It operates through the following segments: Gas-Powered Boats, Electric Boat and Development, and Franchise.

Agenus (AGEN)

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Q32 Bio (QTTB)

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.

Direxion Daily PLTR Bear 1X Shares (PLTD)